| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | estrogen response element binding | 3.74e-05 | 11 | 17 | 2 | GO:0034056 | |
| GeneOntologyMolecularFunction | hormone binding | 8.60e-05 | 103 | 17 | 3 | GO:0042562 | |
| GeneOntologyMolecularFunction | RNA polymerase II general transcription initiation factor binding | 2.36e-04 | 27 | 17 | 2 | GO:0001091 | |
| GeneOntologyMolecularFunction | ADP binding | 7.52e-04 | 48 | 17 | 2 | GO:0043531 | |
| GeneOntologyMolecularFunction | transcription coactivator binding | 9.51e-04 | 54 | 17 | 2 | GO:0001223 | |
| GeneOntologyMolecularFunction | nuclear receptor activity | 1.17e-03 | 60 | 17 | 2 | GO:0004879 | |
| GeneOntologyMolecularFunction | ligand-activated transcription factor activity | 1.21e-03 | 61 | 17 | 2 | GO:0098531 | |
| GeneOntologyMolecularFunction | general transcription initiation factor binding | 1.33e-03 | 64 | 17 | 2 | GO:0140296 | |
| GeneOntologyMolecularFunction | basal RNA polymerase II transcription machinery binding | 1.42e-03 | 66 | 17 | 2 | GO:0001099 | |
| GeneOntologyMolecularFunction | basal transcription machinery binding | 1.42e-03 | 66 | 17 | 2 | GO:0001098 | |
| GeneOntologyMolecularFunction | ATPase binding | 3.74e-03 | 108 | 17 | 2 | GO:0051117 | |
| GeneOntologyMolecularFunction | beta-catenin binding | 4.59e-03 | 120 | 17 | 2 | GO:0008013 | |
| GeneOntologyMolecularFunction | RNA polymerase II-specific DNA-binding transcription factor binding | 4.95e-03 | 417 | 17 | 3 | GO:0061629 | |
| GeneOntologyMolecularFunction | ATP-dependent activity, acting on DNA | 5.13e-03 | 127 | 17 | 2 | GO:0008094 | |
| GeneOntologyMolecularFunction | protein domain specific binding | 5.52e-03 | 875 | 17 | 4 | GO:0019904 | |
| GeneOntologyMolecularFunction | steroid binding | 5.61e-03 | 133 | 17 | 2 | GO:0005496 | |
| GeneOntologyMolecularFunction | G protein-coupled receptor activity | 5.72e-03 | 884 | 17 | 4 | GO:0004930 | |
| GeneOntologyMolecularFunction | RNA polymerase II transcription regulatory region sequence-specific DNA binding | 6.09e-03 | 1459 | 17 | 5 | GO:0000977 | |
| GeneOntologyMolecularFunction | transcription coregulator binding | 6.20e-03 | 140 | 17 | 2 | GO:0001221 | |
| GeneOntologyMolecularFunction | nuclear receptor binding | 1.08e-02 | 187 | 17 | 2 | GO:0016922 | |
| GeneOntologyMolecularFunction | DNA-binding transcription factor binding | 1.24e-02 | 582 | 17 | 3 | GO:0140297 | |
| GeneOntologyBiologicalProcess | mammary gland branching involved in pregnancy | 1.34e-05 | 7 | 17 | 2 | GO:0060745 | |
| GeneOntologyBiologicalProcess | positive regulation of nitric-oxide synthase activity | 7.62e-05 | 16 | 17 | 2 | GO:0051000 | |
| GeneOntologyBiologicalProcess | prostate gland growth | 7.62e-05 | 16 | 17 | 2 | GO:0060736 | |
| GeneOntologyBiologicalProcess | mammary gland alveolus development | 1.46e-04 | 22 | 17 | 2 | GO:0060749 | |
| GeneOntologyBiologicalProcess | mammary gland lobule development | 1.46e-04 | 22 | 17 | 2 | GO:0061377 | |
| GeneOntologyBiologicalProcess | protein localization to chromosome | 1.94e-04 | 140 | 17 | 3 | GO:0034502 | |
| GeneOntologyBiologicalProcess | negative regulation of apoptotic process | 1.99e-04 | 1133 | 17 | 6 | GO:0043066 | |
| GeneOntologyBiologicalProcess | positive regulation of monooxygenase activity | 2.22e-04 | 27 | 17 | 2 | GO:0032770 | |
| GeneOntologyBiologicalProcess | negative regulation of programmed cell death | 2.38e-04 | 1171 | 17 | 6 | GO:0043069 | |
| GeneOntologyBiologicalProcess | regulation of nitric-oxide synthase activity | 2.56e-04 | 29 | 17 | 2 | GO:0050999 | |
| GeneOntologyBiologicalProcess | branching involved in mammary gland duct morphogenesis | 2.74e-04 | 30 | 17 | 2 | GO:0060444 | |
| GeneOntologyBiologicalProcess | prostate gland epithelium morphogenesis | 3.33e-04 | 33 | 17 | 2 | GO:0060740 | |
| GeneOntologyBiologicalProcess | male gonad development | 3.50e-04 | 171 | 17 | 3 | GO:0008584 | |
| GeneOntologyBiologicalProcess | prostate gland morphogenesis | 3.53e-04 | 34 | 17 | 2 | GO:0060512 | |
| GeneOntologyBiologicalProcess | development of primary male sexual characteristics | 3.56e-04 | 172 | 17 | 3 | GO:0046546 | |
| GeneOntologyBiologicalProcess | cellular response to estrogen stimulus | 4.19e-04 | 37 | 17 | 2 | GO:0071391 | |
| GeneOntologyBiologicalProcess | male sex differentiation | 5.44e-04 | 199 | 17 | 3 | GO:0046661 | |
| GeneOntologyBiologicalProcess | regulation of monooxygenase activity | 5.93e-04 | 44 | 17 | 2 | GO:0032768 | |
| GeneOntologyBiologicalProcess | mammary gland duct morphogenesis | 6.20e-04 | 45 | 17 | 2 | GO:0060603 | |
| GeneOntologyBiologicalProcess | positive regulation of oxidoreductase activity | 6.48e-04 | 46 | 17 | 2 | GO:0051353 | |
| GeneOntologyBiologicalProcess | positive regulation of molecular function | 6.99e-04 | 1430 | 17 | 6 | GO:0044093 | |
| GeneOntologyBiologicalProcess | negative regulation of cold-induced thermogenesis | 7.05e-04 | 48 | 17 | 2 | GO:0120163 | |
| GeneOntologyBiologicalProcess | genitalia development | 8.92e-04 | 54 | 17 | 2 | GO:0048806 | |
| GeneOntologyBiologicalProcess | estrogen receptor signaling pathway | 9.94e-04 | 57 | 17 | 2 | GO:0030520 | |
| GeneOntologyBiologicalProcess | prostate gland development | 1.17e-03 | 62 | 17 | 2 | GO:0030850 | |
| GeneOntologyBiologicalProcess | mammary gland morphogenesis | 1.29e-03 | 65 | 17 | 2 | GO:0060443 | |
| GeneOntologyBiologicalProcess | regulation of morphogenesis of a branching structure | 1.29e-03 | 65 | 17 | 2 | GO:0060688 | |
| GeneOntologyBiologicalProcess | epithelial cell development | 1.30e-03 | 269 | 17 | 3 | GO:0002064 | |
| GeneOntologyBiologicalProcess | maternal process involved in female pregnancy | 1.62e-03 | 73 | 17 | 2 | GO:0060135 | |
| GeneOntologyBiologicalProcess | gonad development | 1.65e-03 | 292 | 17 | 3 | GO:0008406 | |
| GeneOntologyBiologicalProcess | development of primary sexual characteristics | 1.73e-03 | 297 | 17 | 3 | GO:0045137 | |
| GeneOntologyBiologicalProcess | regulation of morphogenesis of an epithelium | 1.76e-03 | 76 | 17 | 2 | GO:1905330 | |
| GeneOntologyBiologicalProcess | urogenital system development | 1.90e-03 | 79 | 17 | 2 | GO:0001655 | |
| GeneOntologyBiologicalProcess | regulation of miRNA transcription | 2.09e-03 | 83 | 17 | 2 | GO:1902893 | |
| GeneOntologyBiologicalProcess | miRNA transcription | 2.14e-03 | 84 | 17 | 2 | GO:0061614 | |
| GeneOntologyBiologicalProcess | mammary gland epithelium development | 2.14e-03 | 84 | 17 | 2 | GO:0061180 | |
| GeneOntologyBiologicalProcess | regulation of oxidoreductase activity | 2.14e-03 | 84 | 17 | 2 | GO:0051341 | |
| GeneOntologyBiologicalProcess | negative regulation of muscle cell apoptotic process | 2.30e-03 | 87 | 17 | 2 | GO:0010656 | |
| GeneOntologyBiologicalProcess | negative regulation of smooth muscle cell proliferation | 2.45e-03 | 90 | 17 | 2 | GO:0048662 | |
| GeneOntologyBiologicalProcess | cellular response to hormone stimulus | 2.52e-03 | 727 | 17 | 4 | GO:0032870 | |
| GeneOntologyBiologicalProcess | developmental process involved in reproduction | 2.58e-03 | 1235 | 17 | 5 | GO:0003006 | |
| GeneOntologyBiologicalProcess | sex differentiation | 2.81e-03 | 352 | 17 | 3 | GO:0007548 | |
| GeneOntologyBiologicalProcess | response to estrogen | 3.20e-03 | 103 | 17 | 2 | GO:0043627 | |
| GeneOntologyBiologicalProcess | regulation of miRNA metabolic process | 3.20e-03 | 103 | 17 | 2 | GO:2000628 | |
| HumanPheno | Increased serum estradiol | 4.15e-05 | 9 | 6 | 2 | HP:0025134 | |
| HumanPheno | Elevated alkaline phosphatase of bone origin | 8.97e-05 | 13 | 6 | 2 | HP:0010639 | |
| HumanPheno | Elevated tissue non-specific alkaline phosphatase | 1.56e-04 | 17 | 6 | 2 | HP:0010679 | |
| HumanPheno | Elevated circulating alkaline phosphatase concentration | 2.30e-04 | 118 | 6 | 3 | HP:0003155 | |
| HumanPheno | Abnormality of alkaline phosphatase level | 3.14e-04 | 131 | 6 | 3 | HP:0004379 | |
| MousePheno | motor neuron degeneration | 3.01e-06 | 38 | 11 | 3 | MP:0000938 | |
| MousePheno | increased body size | 8.36e-06 | 409 | 11 | 5 | MP:0001264 | |
| MousePheno | skeletal muscle atrophy | 8.80e-06 | 54 | 11 | 3 | MP:0009417 | |
| MousePheno | preneoplasia | 2.02e-05 | 9 | 11 | 2 | MP:0002009 | |
| MousePheno | decreased skeletal muscle size | 2.99e-05 | 81 | 11 | 3 | MP:0010240 | |
| MousePheno | abnormal skeletal muscle size | 4.53e-05 | 93 | 11 | 3 | MP:0009458 | |
| MousePheno | abnormal epididymal fat pad weight | 4.67e-05 | 94 | 11 | 3 | MP:0020998 | |
| MousePheno | muscular atrophy | 4.98e-05 | 96 | 11 | 3 | MP:0002269 | |
| MousePheno | abnormal white fat cell size | 5.62e-05 | 100 | 11 | 3 | MP:0009132 | |
| MousePheno | premature death | 5.92e-05 | 1051 | 11 | 6 | MP:0002083 | |
| MousePheno | abnormal white adipose tissue morphology | 7.93e-05 | 321 | 11 | 4 | MP:0002970 | |
| MousePheno | abnormal epididymal fat pad morphology | 1.12e-04 | 126 | 11 | 3 | MP:0006319 | |
| MousePheno | abnormal white fat cell morphology | 1.15e-04 | 127 | 11 | 3 | MP:0009117 | |
| MousePheno | decreased tumor-free survival time | 1.17e-04 | 21 | 11 | 2 | MP:0014237 | |
| MousePheno | abnormal tumor-free survival time | 1.17e-04 | 21 | 11 | 2 | MP:0014235 | |
| MousePheno | decreased skeletal muscle mass | 1.26e-04 | 131 | 11 | 3 | MP:0004819 | |
| MousePheno | increased total tissue mass | 1.29e-04 | 364 | 11 | 4 | MP:0012323 | |
| MousePheno | increased body weight | 1.29e-04 | 364 | 11 | 4 | MP:0001260 | |
| MousePheno | small dorsal root ganglion | 1.54e-04 | 24 | 11 | 2 | MP:0000964 | |
| MousePheno | increased circulating testosterone level | 1.81e-04 | 26 | 11 | 2 | MP:0002781 | |
| MousePheno | abnormal skeletal muscle mass | 1.84e-04 | 149 | 11 | 3 | MP:0004817 | |
| MousePheno | abnormal motor neuron morphology | 1.91e-04 | 151 | 11 | 3 | MP:0000937 | |
| MousePheno | skeletal muscle fiber atrophy | 2.26e-04 | 29 | 11 | 2 | MP:0009413 | |
| MousePheno | abnormal muscle electrophysiology | 2.76e-04 | 32 | 11 | 2 | MP:0004145 | |
| MousePheno | abnormal macrophage morphology | 3.26e-04 | 463 | 11 | 4 | MP:0002446 | |
| MousePheno | abnormal spinal cord grey matter morphology | 3.26e-04 | 181 | 11 | 3 | MP:0008503 | |
| MousePheno | increased circulating luteinizing hormone level | 3.30e-04 | 35 | 11 | 2 | MP:0001751 | |
| MousePheno | neurodegeneration | 3.39e-04 | 468 | 11 | 4 | MP:0002229 | |
| MousePheno | increased luteinizing hormone level | 3.90e-04 | 38 | 11 | 2 | MP:0005133 | |
| MousePheno | abnormal mammary gland morphology | 4.44e-04 | 201 | 11 | 3 | MP:0000627 | |
| MousePheno | abnormal apocrine gland morphology | 4.44e-04 | 201 | 11 | 3 | MP:0013554 | |
| MousePheno | abnormal skeletal muscle morphology | 4.64e-04 | 508 | 11 | 4 | MP:0000759 | |
| MousePheno | abnormal retroperitoneal fat pad morphology | 4.99e-04 | 43 | 11 | 2 | MP:0005337 | |
| MousePheno | increased variability of skeletal muscle fiber size | 4.99e-04 | 43 | 11 | 2 | MP:0009403 | |
| MousePheno | increased circulating follicle stimulating hormone level | 5.23e-04 | 44 | 11 | 2 | MP:0001750 | |
| MousePheno | increased follicle stimulating hormone level | 5.97e-04 | 47 | 11 | 2 | MP:0005131 | |
| MousePheno | kyphosis | 6.50e-04 | 229 | 11 | 3 | MP:0000160 | |
| MousePheno | abnormal vagina morphology | 7.03e-04 | 51 | 11 | 2 | MP:0001139 | |
| MousePheno | abnormal external male genitalia morphology | 7.59e-04 | 53 | 11 | 2 | MP:0009199 | |
| MousePheno | abnormal fat cell morphology | 7.63e-04 | 242 | 11 | 3 | MP:0009115 | |
| MousePheno | increased reproductive system tumor incidence | 8.78e-04 | 57 | 11 | 2 | MP:0010287 | |
| MousePheno | testicular atrophy | 9.40e-04 | 59 | 11 | 2 | MP:0003205 | |
| MousePheno | abnormal muscle morphology | 9.47e-04 | 1106 | 11 | 5 | MP:0002108 | |
| MousePheno | abnormal abdominal fat pad morphology | 9.61e-04 | 262 | 11 | 3 | MP:0000010 | |
| MousePheno | decreased circulating gonadotropin level | 9.72e-04 | 60 | 11 | 2 | MP:0003363 | |
| MousePheno | decreased circulating testosterone level | 9.72e-04 | 60 | 11 | 2 | MP:0002780 | |
| MousePheno | increased circulating mineral level | 1.02e-03 | 626 | 11 | 4 | MP:0014547 | |
| MousePheno | abnormal mammary gland duct morphology | 1.04e-03 | 62 | 11 | 2 | MP:0009503 | |
| MousePheno | increased circulating gonadotropin level | 1.11e-03 | 64 | 11 | 2 | MP:0003362 | |
| MousePheno | abnormal luteinizing hormone level | 1.11e-03 | 64 | 11 | 2 | MP:0003969 | |
| MousePheno | decreased epididymal fat pad weight | 1.14e-03 | 65 | 11 | 2 | MP:0009289 | |
| MousePheno | abnormal spinal cord morphology | 1.14e-03 | 278 | 11 | 3 | MP:0000955 | |
| MousePheno | decreased white fat cell size | 1.21e-03 | 67 | 11 | 2 | MP:0009133 | |
| MousePheno | abnormal inguinal fat pad morphology | 1.28e-03 | 69 | 11 | 2 | MP:0005336 | |
| MousePheno | increased mineral level | 1.30e-03 | 668 | 11 | 4 | MP:0014535 | |
| MousePheno | abnormal mesonephros morphology | 1.40e-03 | 72 | 11 | 2 | MP:0008487 | |
| MousePheno | abnormal mammary gland epithelium morphology | 1.47e-03 | 74 | 11 | 2 | MP:0009504 | |
| MousePheno | abnormal somatic sensory system morphology | 1.57e-03 | 702 | 11 | 4 | MP:0000959 | |
| MousePheno | abnormal mononuclear phagocyte morphology | 1.59e-03 | 705 | 11 | 4 | MP:0008248 | |
| MousePheno | abnormal osteoblast cell number | 1.59e-03 | 77 | 11 | 2 | MP:0004987 | |
| MousePheno | abnormal fat pad morphology | 1.62e-03 | 314 | 11 | 3 | MP:0005334 | |
| MousePheno | abnormal spine curvature | 1.68e-03 | 318 | 11 | 3 | MP:0004174 | |
| MousePheno | centrally nucleated skeletal muscle fibers | 1.72e-03 | 80 | 11 | 2 | MP:0009404 | |
| MousePheno | abnormal professional antigen presenting cell morphology | 1.78e-03 | 726 | 11 | 4 | MP:0008195 | |
| MousePheno | abnormal circulating testosterone level | 1.89e-03 | 84 | 11 | 2 | MP:0005180 | |
| MousePheno | abnormal circulating androgen level | 1.89e-03 | 84 | 11 | 2 | MP:0009819 | |
| MousePheno | abnormal myeloid leukocyte morphology | 1.92e-03 | 1292 | 11 | 5 | MP:0008250 | |
| MousePheno | abnormal reflex | 1.94e-03 | 1294 | 11 | 5 | MP:0001961 | |
| MousePheno | abnormal cartilage morphology | 1.97e-03 | 336 | 11 | 3 | MP:0000163 | |
| MousePheno | decreased circulating pituitary hormone level | 2.12e-03 | 89 | 11 | 2 | MP:0005118 | |
| MousePheno | abnormal follicle stimulating hormone level | 2.12e-03 | 89 | 11 | 2 | MP:0003967 | |
| MousePheno | axon degeneration | 2.22e-03 | 91 | 11 | 2 | MP:0005405 | |
| MousePheno | hunched posture | 2.22e-03 | 91 | 11 | 2 | MP:0001505 | |
| MousePheno | abnormal testosterone level | 2.27e-03 | 92 | 11 | 2 | MP:0011385 | |
| MousePheno | abnormal vertebral column morphology | 2.39e-03 | 787 | 11 | 4 | MP:0004703 | |
| MousePheno | abnormal adipose tissue morphology | 2.43e-03 | 1361 | 11 | 5 | MP:0000003 | |
| MousePheno | decreased skeletal muscle fiber size | 2.52e-03 | 97 | 11 | 2 | MP:0009400 | |
| MousePheno | decreased fat cell size | 2.52e-03 | 97 | 11 | 2 | MP:0009269 | |
| MousePheno | adipose tissue phenotype | 2.61e-03 | 1383 | 11 | 5 | MP:0005375 | |
| Domain | zf-C4 | 6.11e-04 | 46 | 15 | 2 | PF00105 | |
| Domain | NUCLEAR_REC_DBD_1 | 6.11e-04 | 46 | 15 | 2 | PS00031 | |
| Domain | Znf_hrmn_rcpt | 6.11e-04 | 46 | 15 | 2 | IPR001628 | |
| Domain | ZnF_C4 | 6.11e-04 | 46 | 15 | 2 | SM00399 | |
| Domain | NUCLEAR_REC_DBD_2 | 6.11e-04 | 46 | 15 | 2 | PS51030 | |
| Domain | - | 6.37e-04 | 47 | 15 | 2 | 1.10.565.10 | |
| Domain | Nucl_hrmn_rcpt_lig-bd | 6.65e-04 | 48 | 15 | 2 | IPR000536 | |
| Domain | Hormone_recep | 6.65e-04 | 48 | 15 | 2 | PF00104 | |
| Domain | HOLI | 6.65e-04 | 48 | 15 | 2 | SM00430 | |
| Domain | - | 9.37e-04 | 57 | 15 | 2 | 3.30.50.10 | |
| Domain | Znf_NHR/GATA | 9.70e-04 | 58 | 15 | 2 | IPR013088 | |
| Domain | Filament | 1.45e-03 | 71 | 15 | 2 | SM01391 | |
| Domain | IF | 1.66e-03 | 76 | 15 | 2 | IPR001664 | |
| Domain | zf-C2H2 | 1.66e-02 | 693 | 15 | 3 | PF00096 | |
| Domain | ZINC_FINGER_C2H2_2 | 2.23e-02 | 775 | 15 | 3 | PS50157 | |
| Domain | ZINC_FINGER_C2H2_1 | 2.24e-02 | 777 | 15 | 3 | PS00028 | |
| Domain | Znf_C2H2-like | 2.39e-02 | 796 | 15 | 3 | IPR015880 | |
| Domain | Znf_C2H2 | 2.46e-02 | 805 | 15 | 3 | IPR007087 | |
| Domain | ZnF_C2H2 | 2.49e-02 | 808 | 15 | 3 | SM00355 | |
| Domain | zf-C2H2_6 | 2.56e-02 | 314 | 15 | 2 | PF13912 | |
| Pathway | WP_ANDROGEN_RECEPTOR_NETWORK_IN_PROSTATE_CANCER | 5.33e-05 | 110 | 10 | 3 | M48043 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_BY_RUNX2 | 6.74e-05 | 119 | 10 | 3 | M27785 | |
| Pathway | REACTOME_RUNX2_REGULATES_OSTEOBLAST_DIFFERENTIATION | 1.24e-04 | 24 | 10 | 2 | M27803 | |
| Pathway | REACTOME_SUMOYLATION_OF_INTRACELLULAR_RECEPTORS | 1.70e-04 | 28 | 10 | 2 | MM15042 | |
| Pathway | REACTOME_SUMOYLATION_OF_INTRACELLULAR_RECEPTORS | 1.95e-04 | 30 | 10 | 2 | M27323 | |
| Pathway | REACTOME_RUNX2_REGULATES_BONE_DEVELOPMENT | 2.08e-04 | 31 | 10 | 2 | M27805 | |
| Pathway | WP_CANCER_PATHWAYS | 2.92e-04 | 507 | 10 | 4 | M48302 | |
| Pathway | WP_NUCLEAR_RECEPTORS | 3.14e-04 | 38 | 10 | 2 | MM15865 | |
| Pathway | WP_NUCLEAR_RECEPTORS | 3.14e-04 | 38 | 10 | 2 | M39657 | |
| Pathway | PID_FOXM1_PATHWAY | 3.48e-04 | 40 | 10 | 2 | M176 | |
| Pathway | PID_HNF3A_PATHWAY | 4.22e-04 | 44 | 10 | 2 | M285 | |
| Pathway | WP_ARYL_HYDROCARBON_RECEPTOR_PATHWAY_WP2586 | 4.61e-04 | 46 | 10 | 2 | M39661 | |
| Pathway | PID_HES_HEY_PATHWAY | 5.02e-04 | 48 | 10 | 2 | M288 | |
| Pathway | REACTOME_NUCLEAR_RECEPTOR_TRANSCRIPTION_PATHWAY | 5.02e-04 | 48 | 10 | 2 | MM14987 | |
| Pathway | WP_INTEGRATED_CANCER_PATHWAY | 5.02e-04 | 48 | 10 | 2 | M39628 | |
| Pathway | REACTOME_NUCLEAR_RECEPTOR_TRANSCRIPTION_PATHWAY | 6.12e-04 | 53 | 10 | 2 | M8276 | |
| Pathway | PID_ATF2_PATHWAY | 7.58e-04 | 59 | 10 | 2 | M166 | |
| Pathway | KEGG_PATHWAYS_IN_CANCER | 1.29e-03 | 325 | 10 | 3 | M12868 | |
| Pathway | PID_SMAD2_3NUCLEAR_PATHWAY | 1.46e-03 | 82 | 10 | 2 | M2 | |
| Pathway | WP_GLIOBLASTOMA_SIGNALING | 1.49e-03 | 83 | 10 | 2 | M39637 | |
| Pathway | KEGG_PROSTATE_CANCER | 1.72e-03 | 89 | 10 | 2 | M13191 | |
| Pathway | WP_RETINOBLASTOMA_GENE_IN_CANCER | 1.75e-03 | 90 | 10 | 2 | M39678 | |
| Pathway | WP_ANDROGEN_RECEPTOR_SIGNALING | 1.79e-03 | 91 | 10 | 2 | M39700 | |
| Pathway | WP_IL6_SIGNALING_PATHWAY | 2.16e-03 | 100 | 10 | 2 | MM15826 | |
| Pathway | REACTOME_DISEASES_OF_SIGNAL_TRANSDUCTION_BY_GROWTH_FACTOR_RECEPTORS_AND_SECOND_MESSENGERS | 3.58e-03 | 464 | 10 | 3 | M27547 | |
| Pathway | WP_MALE_INFERTILITY | 4.48e-03 | 145 | 10 | 2 | M39856 | |
| Pathway | WP_BREAST_CANCER_PATHWAY | 5.04e-03 | 154 | 10 | 2 | M39739 | |
| Pathway | REACTOME_SUMOYLATION | 6.04e-03 | 169 | 10 | 2 | MM14919 | |
| Pathway | REACTOME_SUMOYLATION | 7.50e-03 | 189 | 10 | 2 | M27214 | |
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 25076121 | ||
| Pubmed | The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. | 2.25e-07 | 2 | 17 | 2 | 33462444 | |
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 23023562 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 18559568 | ||
| Pubmed | Estren behaves as a weak estrogen rather than a nongenomic selective activator in the mouse uterus. | 2.25e-07 | 2 | 17 | 2 | 16469803 | |
| Pubmed | Expression of estrogen and androgen receptors in children with hypospadias: preliminary report. | 2.25e-07 | 2 | 17 | 2 | 17453687 | |
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 27402268 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 20846920 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 21099110 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 9675141 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 27148695 | ||
| Pubmed | Direct androgen receptor control of sexually dimorphic gene expression in the mammalian kidney. | 2.25e-07 | 2 | 17 | 2 | 37673062 | |
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 32392092 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 12031042 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 17187234 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 35618789 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 28974548 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 17638386 | ||
| Pubmed | The Role of the Androgen Receptor Signaling in Breast Malignancies. | 2.25e-07 | 2 | 17 | 2 | 29187427 | |
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 12389206 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 26264910 | ||
| Pubmed | The role of estrogen receptors and androgen receptors in sex steroid regulation of B lymphopoiesis. | 2.25e-07 | 2 | 17 | 2 | 9647203 | |
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 27466486 | ||
| Pubmed | Androgen signaling negatively controls group 2 innate lymphoid cells. | 2.25e-07 | 2 | 17 | 2 | 28484078 | |
| Pubmed | Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies. | 2.25e-07 | 2 | 17 | 2 | 30445651 | |
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 35640239 | ||
| Pubmed | The association of androgen- and oestrogen-receptor gene polymorphisms with urolithiasis in men. | 2.25e-07 | 2 | 17 | 2 | 11564035 | |
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 32344660 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 25904752 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 18809737 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 25599767 | ||
| Pubmed | Association of receptor expression with prostate volume in benign prostatic hyperplasia. | 2.25e-07 | 2 | 17 | 2 | 30706868 | |
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 33323970 | ||
| Pubmed | Differential DNase I hypersensitivity reveals factor-dependent chromatin dynamics. | 2.25e-07 | 2 | 17 | 2 | 22508765 | |
| Pubmed | Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein. | 2.25e-07 | 2 | 17 | 2 | 27760327 | |
| Pubmed | Sex hormones regulate metainflammation in diet-induced obesity in mice. | 2.25e-07 | 2 | 17 | 2 | 34599964 | |
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 20353269 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 23996526 | ||
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 14960012 | ||
| Pubmed | AR collaborates with ERα in aromatase inhibitor-resistant breast cancer. | 2.25e-07 | 2 | 17 | 2 | 25178514 | |
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 15827868 | ||
| Pubmed | Androgen receptor disruption increases the osteogenic response to mechanical loading in male mice. | 2.25e-07 | 2 | 17 | 2 | 19821763 | |
| Pubmed | Differential regulation of androgen and glucocorticoid receptors by retinoblastoma protein. | 2.25e-07 | 2 | 17 | 2 | 9813067 | |
| Pubmed | Expression of sexual hormones receptors in oral squamous cell carcinoma. | 2.25e-07 | 2 | 17 | 2 | 21781458 | |
| Pubmed | Genomics of sex hormone receptor signaling in hepatic sexual dimorphism. | 2.25e-07 | 2 | 17 | 2 | 28554805 | |
| Pubmed | 2.25e-07 | 2 | 17 | 2 | 32109207 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 16166216 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 16123086 | ||
| Pubmed | Localization of steroid hormone receptors in the apocrine sweat glands of the human axilla. | 6.74e-07 | 3 | 17 | 2 | 15609040 | |
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 24680642 | ||
| Pubmed | Association between estrogen and androgen receptor genes and prostate cancer risk. | 6.74e-07 | 3 | 17 | 2 | 18952763 | |
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 33788729 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 15654614 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 20435684 | ||
| Pubmed | Microsatellite profile in hormonal receptor genes associated with breast cancer. | 6.74e-07 | 3 | 17 | 2 | 16317584 | |
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 25704845 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 26043844 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 30250632 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 16223864 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 19592451 | ||
| Pubmed | Steroid hormones polymorphisms and cholelithiasis in Greek population. | 6.74e-07 | 3 | 17 | 2 | 17241382 | |
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 25979597 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 15541640 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 30513371 | ||
| Pubmed | Associations between ERalpha, ERbeta, and AR genotypes and colon and rectal cancer. | 6.74e-07 | 3 | 17 | 2 | 16365013 | |
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 37246005 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 16647340 | ||
| Pubmed | Microsatellite variation of ESR1, ESR2, and AR in Serbian women with primary ovarian insufficiency. | 6.74e-07 | 3 | 17 | 2 | 30156935 | |
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 32593802 | ||
| Pubmed | Estrogens and development of the mouse and human external genitalia. | 6.74e-07 | 3 | 17 | 2 | 33092894 | |
| Pubmed | Expression of androgen and estrogen receptors in human scalp mesenchymal cells in vitro. | 6.74e-07 | 3 | 17 | 2 | 17160687 | |
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 11397855 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 37335379 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 12727923 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 11595700 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 14645241 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 27992601 | ||
| Pubmed | Targeting androgen receptor in estrogen receptor-negative breast cancer. | 6.74e-07 | 3 | 17 | 2 | 21741601 | |
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 22531679 | ||
| Pubmed | Neuroendocrine stress response is moderated by sex and sex hormone receptor polymorphisms. | 6.74e-07 | 3 | 17 | 2 | 30300610 | |
| Pubmed | Hormonal receptors in lung adenocarcinoma: expression and difference in outcome by sex. | 6.74e-07 | 3 | 17 | 2 | 27690341 | |
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 20299092 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 16098017 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 14747651 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 12895004 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 16046054 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 15536156 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 23580588 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 17365134 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 16791593 | ||
| Pubmed | Expression, distribution and regulation of sex steroid hormone receptors in mouse heart. | 6.74e-07 | 3 | 17 | 2 | 19255502 | |
| Pubmed | Prohibitin promotes androgen receptor activation in ER-positive breast cancer. | 6.74e-07 | 3 | 17 | 2 | 28272969 | |
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 15205473 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 20615892 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 28539237 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 20439495 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 17904846 | ||
| Pubmed | Localization of androgen and estrogen receptors in adult male mouse reproductive tract. | 6.74e-07 | 3 | 17 | 2 | 12399534 | |
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 18297304 | ||
| Pubmed | 6.74e-07 | 3 | 17 | 2 | 15772083 | ||
| Interaction | SKIL interactions | 1.99e-06 | 119 | 16 | 4 | int:SKIL | |
| Interaction | CCND1 interactions | 2.14e-06 | 286 | 16 | 5 | int:CCND1 | |
| Interaction | KDM4A interactions | 1.66e-05 | 64 | 16 | 3 | int:KDM4A | |
| Interaction | UHRF1 interactions | 1.82e-05 | 208 | 16 | 4 | int:UHRF1 | |
| Interaction | MED13 interactions | 4.04e-05 | 86 | 16 | 3 | int:MED13 | |
| Interaction | POU2F3 interactions | 6.17e-05 | 15 | 16 | 2 | int:POU2F3 | |
| Interaction | LIMCH1 interactions | 6.33e-05 | 100 | 16 | 3 | int:LIMCH1 | |
| Interaction | FLII interactions | 7.41e-05 | 298 | 16 | 4 | int:FLII | |
| Interaction | CREBBP interactions | 7.59e-05 | 599 | 16 | 5 | int:CREBBP | |
| Interaction | GTF2H1 interactions | 7.75e-05 | 107 | 16 | 3 | int:GTF2H1 | |
| Interaction | LIN9 interactions | 8.64e-05 | 111 | 16 | 3 | int:LIN9 | |
| Interaction | TFAP2A interactions | 9.36e-05 | 114 | 16 | 3 | int:TFAP2A | |
| Interaction | LDB1 interactions | 9.60e-05 | 115 | 16 | 3 | int:LDB1 | |
| Interaction | ITPRID2 interactions | 1.09e-04 | 120 | 16 | 3 | int:ITPRID2 | |
| Interaction | RBM26 interactions | 1.38e-04 | 130 | 16 | 3 | int:RBM26 | |
| Interaction | ZBTB7A interactions | 1.41e-04 | 131 | 16 | 3 | int:ZBTB7A | |
| Interaction | AHR interactions | 1.45e-04 | 132 | 16 | 3 | int:AHR | |
| Interaction | TOLLIP interactions | 1.50e-04 | 358 | 16 | 4 | int:TOLLIP | |
| Interaction | CDC25B interactions | 1.51e-04 | 134 | 16 | 3 | int:CDC25B | |
| Interaction | GRHL2 interactions | 1.75e-04 | 25 | 16 | 2 | int:GRHL2 | |
| Interaction | HDAC7 interactions | 1.76e-04 | 141 | 16 | 3 | int:HDAC7 | |
| Interaction | POU2F2 interactions | 1.90e-04 | 26 | 16 | 2 | int:POU2F2 | |
| Interaction | NCOA6 interactions | 1.91e-04 | 145 | 16 | 3 | int:NCOA6 | |
| Interaction | CDC42BPA interactions | 1.95e-04 | 146 | 16 | 3 | int:CDC42BPA | |
| Interaction | BRD8 interactions | 2.07e-04 | 149 | 16 | 3 | int:BRD8 | |
| Interaction | TRIB3 interactions | 2.55e-04 | 160 | 16 | 3 | int:TRIB3 | |
| Interaction | SKI interactions | 2.55e-04 | 160 | 16 | 3 | int:SKI | |
| Interaction | CGREF1 interactions | 2.71e-04 | 31 | 16 | 2 | int:CGREF1 | |
| Interaction | GRB2 interactions | 3.05e-04 | 806 | 16 | 5 | int:GRB2 | |
| Interaction | RAP1A interactions | 3.10e-04 | 171 | 16 | 3 | int:RAP1A | |
| Interaction | MTA3 interactions | 3.21e-04 | 173 | 16 | 3 | int:MTA3 | |
| Interaction | UBE3A interactions | 3.34e-04 | 441 | 16 | 4 | int:UBE3A | |
| Interaction | HIF1A interactions | 3.34e-04 | 441 | 16 | 4 | int:HIF1A | |
| Interaction | PNRC2 interactions | 3.46e-04 | 35 | 16 | 2 | int:PNRC2 | |
| Interaction | DDHD1 interactions | 3.87e-04 | 37 | 16 | 2 | int:DDHD1 | |
| Interaction | CITED1 interactions | 3.87e-04 | 37 | 16 | 2 | int:CITED1 | |
| Interaction | SMARCA4 interactions | 3.99e-04 | 462 | 16 | 4 | int:SMARCA4 | |
| Interaction | CCAR1 interactions | 4.03e-04 | 187 | 16 | 3 | int:CCAR1 | |
| Interaction | ZBTB16 interactions | 4.03e-04 | 187 | 16 | 3 | int:ZBTB16 | |
| Interaction | PELP1 interactions | 4.16e-04 | 189 | 16 | 3 | int:PELP1 | |
| Interaction | GAK interactions | 4.16e-04 | 189 | 16 | 3 | int:GAK | |
| Interaction | PPP1CB interactions | 4.22e-04 | 469 | 16 | 4 | int:PPP1CB | |
| Interaction | KMT5B interactions | 4.30e-04 | 39 | 16 | 2 | int:KMT5B | |
| Interaction | PPAN interactions | 4.42e-04 | 193 | 16 | 3 | int:PPAN | |
| Interaction | CHD8 interactions | 4.42e-04 | 193 | 16 | 3 | int:CHD8 | |
| Interaction | CRACD interactions | 4.53e-04 | 40 | 16 | 2 | int:CRACD | |
| Interaction | NR0B1 interactions | 4.53e-04 | 40 | 16 | 2 | int:NR0B1 | |
| Interaction | PSMC3IP interactions | 4.76e-04 | 41 | 16 | 2 | int:PSMC3IP | |
| Interaction | PIK3R3 interactions | 4.76e-04 | 198 | 16 | 3 | int:PIK3R3 | |
| Interaction | E2F1 interactions | 4.90e-04 | 200 | 16 | 3 | int:E2F1 | |
| Interaction | GBP1 interactions | 4.99e-04 | 42 | 16 | 2 | int:GBP1 | |
| Interaction | MYO5A interactions | 5.19e-04 | 204 | 16 | 3 | int:MYO5A | |
| Interaction | CASZ1 interactions | 5.24e-04 | 43 | 16 | 2 | int:CASZ1 | |
| Interaction | PRDM2 interactions | 5.24e-04 | 43 | 16 | 2 | int:PRDM2 | |
| Interaction | GSN interactions | 5.81e-04 | 212 | 16 | 3 | int:GSN | |
| Interaction | BCL9L interactions | 6.53e-04 | 48 | 16 | 2 | int:BCL9L | |
| Interaction | MORF4L1 interactions | 6.56e-04 | 221 | 16 | 3 | int:MORF4L1 | |
| Interaction | EXOSC10 interactions | 6.73e-04 | 223 | 16 | 3 | int:EXOSC10 | |
| Interaction | RNF14 interactions | 6.80e-04 | 49 | 16 | 2 | int:RNF14 | |
| Interaction | CCNT1 interactions | 6.91e-04 | 225 | 16 | 3 | int:CCNT1 | |
| Interaction | GTF2H2C interactions | 7.08e-04 | 50 | 16 | 2 | int:GTF2H2C | |
| Interaction | TAF8 interactions | 7.08e-04 | 50 | 16 | 2 | int:TAF8 | |
| Interaction | DDX46 interactions | 7.09e-04 | 227 | 16 | 3 | int:DDX46 | |
| Interaction | TEKT5 interactions | 7.37e-04 | 51 | 16 | 2 | int:TEKT5 | |
| Interaction | PAGR1 interactions | 7.37e-04 | 51 | 16 | 2 | int:PAGR1 | |
| Interaction | NCOA4 interactions | 7.37e-04 | 51 | 16 | 2 | int:NCOA4 | |
| Interaction | RFC1 interactions | 7.45e-04 | 231 | 16 | 3 | int:RFC1 | |
| Interaction | SVIL interactions | 7.64e-04 | 233 | 16 | 3 | int:SVIL | |
| Interaction | NKX3-1 interactions | 7.66e-04 | 52 | 16 | 2 | int:NKX3-1 | |
| Interaction | UBTF interactions | 7.74e-04 | 234 | 16 | 3 | int:UBTF | |
| Interaction | GTF2F1 interactions | 7.74e-04 | 234 | 16 | 3 | int:GTF2F1 | |
| Interaction | GTF2H3 interactions | 7.95e-04 | 53 | 16 | 2 | int:GTF2H3 | |
| Interaction | FOXK1 interactions | 8.13e-04 | 238 | 16 | 3 | int:FOXK1 | |
| Interaction | JARID2 interactions | 8.26e-04 | 54 | 16 | 2 | int:JARID2 | |
| Interaction | WIPI1 interactions | 8.56e-04 | 55 | 16 | 2 | int:WIPI1 | |
| Interaction | VAV3 interactions | 8.56e-04 | 55 | 16 | 2 | int:VAV3 | |
| Interaction | TMOD3 interactions | 8.63e-04 | 243 | 16 | 3 | int:TMOD3 | |
| Interaction | CDC27 interactions | 9.26e-04 | 249 | 16 | 3 | int:CDC27 | |
| Interaction | RBM10 interactions | 9.70e-04 | 253 | 16 | 3 | int:RBM10 | |
| Interaction | TBP interactions | 9.70e-04 | 253 | 16 | 3 | int:TBP | |
| Interaction | NPPA interactions | 9.85e-04 | 59 | 16 | 2 | int:NPPA | |
| Interaction | MYL6 interactions | 9.92e-04 | 255 | 16 | 3 | int:MYL6 | |
| Interaction | ARNT interactions | 9.92e-04 | 255 | 16 | 3 | int:ARNT | |
| Interaction | DSG2 interactions | 1.00e-03 | 256 | 16 | 3 | int:DSG2 | |
| Interaction | PBRM1 interactions | 1.03e-03 | 258 | 16 | 3 | int:PBRM1 | |
| Interaction | AFAP1 interactions | 1.05e-03 | 61 | 16 | 2 | int:AFAP1 | |
| Interaction | RNF40 interactions | 1.06e-03 | 261 | 16 | 3 | int:RNF40 | |
| Interaction | TPM1 interactions | 1.09e-03 | 263 | 16 | 3 | int:TPM1 | |
| Interaction | MED23 interactions | 1.12e-03 | 266 | 16 | 3 | int:MED23 | |
| Interaction | PAX5 interactions | 1.16e-03 | 64 | 16 | 2 | int:PAX5 | |
| Interaction | TTC5 interactions | 1.19e-03 | 65 | 16 | 2 | int:TTC5 | |
| Interaction | MYO1B interactions | 1.21e-03 | 273 | 16 | 3 | int:MYO1B | |
| Interaction | RAD9A interactions | 1.23e-03 | 66 | 16 | 2 | int:RAD9A | |
| Interaction | TOM1L2 interactions | 1.23e-03 | 66 | 16 | 2 | int:TOM1L2 | |
| Interaction | SMYD2 interactions | 1.27e-03 | 67 | 16 | 2 | int:SMYD2 | |
| Interaction | CLP1 interactions | 1.27e-03 | 67 | 16 | 2 | int:CLP1 | |
| Interaction | CORO2A interactions | 1.31e-03 | 68 | 16 | 2 | int:CORO2A | |
| Interaction | PPP1R12B interactions | 1.31e-03 | 68 | 16 | 2 | int:PPP1R12B | |
| Interaction | INTS13 interactions | 1.34e-03 | 69 | 16 | 2 | int:INTS13 | |
| Interaction | SUPT7L interactions | 1.34e-03 | 69 | 16 | 2 | int:SUPT7L | |
| GeneFamily | Intermediate filament family orphans | 7.34e-07 | 2 | 16 | 2 | 614 | |
| GeneFamily | Nuclear hormone receptors | 8.43e-04 | 49 | 16 | 2 | 71 | |
| GeneFamily | Zinc fingers C2H2-type|ZF class homeoboxes and pseudogenes | 2.37e-02 | 718 | 16 | 3 | 28 | |
| Coexpression | PUJANA_BREAST_CANCER_LIT_INT_NETWORK | 4.76e-07 | 101 | 17 | 4 | M15356 | |
| ToppCell | droplet-Liver-Hepatocytes-18m-Endothelial|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.45e-07 | 186 | 17 | 4 | 37860daeecd6d412bd3797f30496a56da667fbd1 | |
| ToppCell | droplet-Liver-Hepatocytes-18m-Endothelial-endothelial_cell_of_hepatic_sinusoid|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.45e-07 | 186 | 17 | 4 | baebeffdd426ce767190ddefc857cc78e6a58d36 | |
| ToppCell | droplet-Liver-Hepatocytes-18m-Endothelial-endothelial_cell_of_hepatic_sinusoid|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.45e-07 | 186 | 17 | 4 | 60830822d3de3147816693404fd03392e04c2b8e | |
| ToppCell | 3'_v3-lymph-node_spleen-Lymphocytic_B-GC_B_(II)|lymph-node_spleen / Manually curated celltypes from each tissue | 2.48e-05 | 152 | 17 | 3 | 4f690aed23338687bdefc47e8a2f3d1fdb2b6447 | |
| ToppCell | 3'_v3-GI_small-bowel-Lymphocytic_T_CD8-Tem/emra_CD8|GI_small-bowel / Manually curated celltypes from each tissue | 3.06e-05 | 163 | 17 | 3 | 1a8c79903ed416f286ebe8a9922233affbc55d82 | |
| ToppCell | normal_Lymph_Node-B_lymphocytes-GrB-secreting_B_cells|normal_Lymph_Node / Location, Cell class and cell subclass | 3.78e-05 | 175 | 17 | 3 | 29fbdfe1d3bfcb063be2bced0128a33176c5b78f | |
| ToppCell | normal_Lymph_Node-B_lymphocytes-GrB-secreting_B_cells|B_lymphocytes / Location, Cell class and cell subclass | 3.84e-05 | 176 | 17 | 3 | d6e660df92a3d7dd5732171ee623763faf108476 | |
| ToppCell | TCGA-Pancreas-Primary_Tumor-Pancreatic_Adenocarcinoma-Ductal_Adenocarcinoma-4|TCGA-Pancreas / Sample_Type by Project: Shred V9 | 4.39e-05 | 184 | 17 | 3 | 67164bb6bcae7322cb89b585c7aa10bce35b0ecd | |
| ToppCell | PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_adventitial_fibro_(10)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 5.06e-05 | 193 | 17 | 3 | adc9fc94f9ec686a417d08c0b8b7b7ab687afec0 | |
| ToppCell | TCGA-Bone_and_Soft_Tissue-Primary_Tumor-Sarcoma-Poorly_Differentiated_or_Epithelioid_Leiomyosarcoma-2|TCGA-Bone_and_Soft_Tissue / Sample_Type by Project: Shred V9 | 8.89e-04 | 117 | 17 | 2 | 94f511dbf639b164c4b096195db312ecee3ee176 | |
| ToppCell | 343B-Lymphocytic-NK_cells-NK_cell_A2|343B / Donor, Lineage, Cell class and subclass (all cells) | 1.15e-03 | 133 | 17 | 2 | 8ff1cf0ea1fc33fe8384c0e65c1ee1853b25a2ae | |
| ToppCell | primary_visual_cortex-Neuronal-GABAergic_neuron-Vip-Vip_Col15a1_Pde1a|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 1.16e-03 | 134 | 17 | 2 | d63fff23040eada31bc35ba1e05b7c6a663e0037 | |
| ToppCell | TCGA-Uvea|World / Sample_Type by Project: Shred V9 | 1.29e-03 | 141 | 17 | 2 | 015451a83087f2705d3315ebc8f23797c6f10ed6 | |
| ToppCell | PND07-28-samps-Mesenchymal-Myofibroblast-MyoFB-3|PND07-28-samps / Age Group, Lineage, Cell class and subclass | 1.29e-03 | 141 | 17 | 2 | 7ae8ead02e5aeb4106c4a30c08a7a061da3a5d6a | |
| ToppCell | TCGA-Breast|World / Sample_Type by Project: Shred V9 | 1.45e-03 | 150 | 17 | 2 | 08686ba1acac5c58667bf62e2af84c691d6bbdfb | |
| ToppCell | TCGA-Bone_and_Soft_Tissue-Primary_Tumor-Sarcoma-Poorly_Differentiated_or_Epithelioid_Leiomyosarcoma|TCGA-Bone_and_Soft_Tissue / Sample_Type by Project: Shred V9 | 1.49e-03 | 152 | 17 | 2 | 6f9c343669883618cd9c1c8921a90c34d153f303 | |
| ToppCell | Control-PLT_4|World / Disease Group and Platelet Clusters | 1.53e-03 | 154 | 17 | 2 | a2a03c5e6759c45aeeedf1e68ecb5a0112ef9a20 | |
| ToppCell | Brain_organoid-organoid_Kanton_Nature-Organoid-1M-Radial_glial-gliogenic/outer_RGCs_and_astrocytes|Organoid-1M / Sample Type, Dataset, Time_group, and Cell type. | 1.59e-03 | 157 | 17 | 2 | 2c1219ee19a6246a3b9f5c2c1a37f26ea934a822 | |
| ToppCell | FLU-Healthy-1|Healthy / Virus stimulation, Condition and Cluster | 1.63e-03 | 159 | 17 | 2 | 97c8e16a7ac10ebba96daee97f9fb1d4a404f23b | |
| ToppCell | FLU-Healthy-1|FLU / Virus stimulation, Condition and Cluster | 1.63e-03 | 159 | 17 | 2 | fe2a9f79b058e89214256e736f6e266830cdfa28 | |
| ToppCell | TCGA-Skin-Metastatic-Melanoma-Skin_Cutaneous_Melanoma-3|TCGA-Skin / Sample_Type by Project: Shred V9 | 1.63e-03 | 159 | 17 | 2 | fb222c42f66901852b01cec073ec0732245ee973 | |
| ToppCell | 390C-Myeloid-Macrophage-SPP1+_Macrophage_2|Macrophage / Donor, Lineage, Cell class and subclass (all cells) | 1.65e-03 | 160 | 17 | 2 | 8aaf6ac4f33ea291387fdbf9ff1a91d559391774 | |
| ToppCell | COVID_non-vent-Lymphocytic-Dendritic-pDC|COVID_non-vent / Disease condition, Lineage, Cell class and subclass | 1.65e-03 | 160 | 17 | 2 | 61f4cb4eb4313d8318aadbb99595a6cb7fd919f7 | |
| ToppCell | COVID_non-vent-Lymphocytic-Dendritic|COVID_non-vent / Disease condition, Lineage, Cell class and subclass | 1.65e-03 | 160 | 17 | 2 | 34b4f710cfcb6ec370b8b074f3cbfe272f392cec | |
| ToppCell | CD8+_Memory_T_cell-FLU-1|CD8+_Memory_T_cell / cell class, Virus stimulation and cluster | 1.69e-03 | 162 | 17 | 2 | 76f39935763848ea6e7917b2f9f1432c543063d9 | |
| ToppCell | Influenza_Severe-cDC|World / Disease group and Cell class | 1.73e-03 | 164 | 17 | 2 | c984228f73b9aa1aaf948541f64f41ed874770cd | |
| ToppCell | LV-11._Adipocyte|World / Chamber and Cluster_Paper | 1.77e-03 | 166 | 17 | 2 | 7e5852891714465c6228c9f955fd511ec79d0e02 | |
| ToppCell | Influenza_Severe-cDC|Influenza_Severe / Disease group and Cell class | 1.77e-03 | 166 | 17 | 2 | b40bdf0f7f381e25be61188e9f6c294d25a8b824 | |
| ToppCell | B_cells-pDCs|World / Immune cells in Kidney/Urine in Lupus Nephritis | 1.82e-03 | 168 | 17 | 2 | dc8f94424f60ab56facdcffa969e7f3466ee1b6e | |
| ToppCell | 3'-GW_trimst-2-LargeIntestine-Mesenchymal-immature_mesenchymal_cell-Mesoderm_1_(HAND1+)|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.84e-03 | 169 | 17 | 2 | 3f738fc56bbc70dc77c9ba41025631f8264cd2b3 | |
| ToppCell | 10x3'2.3-week_17-19-Hematopoietic-HSC/MPP_and_pro-MEMP|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 1.84e-03 | 169 | 17 | 2 | 9a2fedee8ff90513bc2cbe2a65d07575ee8a0b70 | |
| ToppCell | 368C-Myeloid-Macrophage-SPP1+_Macrophage_2|Myeloid / Donor, Lineage, Cell class and subclass (all cells) | 1.84e-03 | 169 | 17 | 2 | c6e5b179461996ced6c7621dc01cec00d401f4e8 | |
| ToppCell | 368C-Myeloid-Macrophage-SPP1+_Macrophage_2|Macrophage / Donor, Lineage, Cell class and subclass (all cells) | 1.84e-03 | 169 | 17 | 2 | ea600c63cf9572bc4b3cad6392f67bd0d92c7fc9 | |
| ToppCell | 368C-Myeloid-Macrophage-SPP1+_Macrophage_2|368C / Donor, Lineage, Cell class and subclass (all cells) | 1.88e-03 | 171 | 17 | 2 | 26b34dc069cc15b75a0c13cb8c5d81e074788160 | |
| ToppCell | ICU-SEP-Myeloid-pDC|ICU-SEP / Disease, Lineage and Cell Type | 1.88e-03 | 171 | 17 | 2 | 72c448a0dc4c569bd6b465f9aa395f38034e7ea6 | |
| ToppCell | 3'-GW_trimst-1.5-LargeIntestine-Mesenchymal-myocytic-SMC_(PART1/CAPN3+)|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.88e-03 | 171 | 17 | 2 | fe0665c5ca01b0b2cc8f20d64587f0847c3d215c | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Immune-Myeloid-Monocytic-Monocyte-derived_Cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 1.90e-03 | 172 | 17 | 2 | f6b4754a7e4b3e38030316a0ae00d932bfa87e41 | |
| ToppCell | wk_15-18-Endothelial-Blood_vessel_endothelial-arterial_endo|wk_15-18 / Celltypes from embryonic and fetal-stage human lung | 1.92e-03 | 173 | 17 | 2 | 3a9e9a09b3eeb37cbe56d650e112a8398879477f | |
| ToppCell | droplet-Trachea-3m-Endothelial-endothelial_cell_of_trachea-tracheal_endothelial_cell-tracheal_endothelial_cell_28|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 1.92e-03 | 173 | 17 | 2 | 66488d01e03264fb193285470901c9c4182fbae8 | |
| ToppCell | LV-11._Adipocyte|LV / Chamber and Cluster_Paper | 1.92e-03 | 173 | 17 | 2 | c2d3fcb3de71015d03d14c63450853d2b03ffa71 | |
| ToppCell | 5'-Parenchyma_lung-Epithelial-Airway_epithelium-respiratory_basal_cell-Basal_resting-Basal_resting_L.0.0.0.0|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.95e-03 | 174 | 17 | 2 | 911eac6f6ec1e5e85348a7fe774243498388a810 | |
| ToppCell | droplet-Lung-21m-Hematologic-lymphocytic-CD8-positive,_alpha-beta_T_cell-CD8-positive,_alpha-beta_T_cell_l21|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 1.99e-03 | 176 | 17 | 2 | 91ad2c34144f72283ca112fd3b3784f2f6259f65 | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Immune-Myeloid-Monocytic|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 1.99e-03 | 176 | 17 | 2 | 926ed37e636fe4dd3a18731cea15761f0c2c285a | |
| ToppCell | 356C-Epithelial_cells-Epithelial-G_(Club-Clara_cells)-|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells) | 2.01e-03 | 177 | 17 | 2 | 709235694cc711b9b79690e23c94577b2ae06811 | |
| ToppCell | 356C-Epithelial_cells-Epithelial-G_(Club-Clara_cells)|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells) | 2.01e-03 | 177 | 17 | 2 | 7f9c2a45a994b32f15e5693f7cb873716a4eb568 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_1-Inh_L1-3_VIP_SSTR1|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.01e-03 | 177 | 17 | 2 | fdab7b7ddfb06f913b8224c0c80574dc3cf4cbd4 | |
| ToppCell | 390C-Endothelial_cells-Endothelial-E|390C / Donor, Lineage, Cell class and subclass (all cells) | 2.04e-03 | 178 | 17 | 2 | ad6dc4a375664c919bd48c35c48a561fc5a7de8c | |
| ToppCell | 390C-Endothelial_cells-Endothelial-E-|390C / Donor, Lineage, Cell class and subclass (all cells) | 2.04e-03 | 178 | 17 | 2 | 804ac3725c1f88e2212172bfb9aa01d97a735621 | |
| ToppCell | human_hepatoblastoma-Tumor_cells-T6|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells) | 2.06e-03 | 179 | 17 | 2 | 14fc8ccb6b215063d747643f47d780d2b237eb67 | |
| ToppCell | droplet-Fat-Gat-18m-Endothelial-nan|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.06e-03 | 179 | 17 | 2 | 08cf9986804a6417a9afb19b50c69a3554f71ec6 | |
| ToppCell | Children_(3_yrs)-Endothelial-endothelial_cell_of_vein-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor | 2.08e-03 | 180 | 17 | 2 | 27e8bbee388e64dd79d70b160b76d45b1f398006 | |
| ToppCell | TCGA-Head_and_Esophagus-Primary_Tumor-Head_and_Neck_Carcinoma-Squamous_Cell_Carcinoma-4|TCGA-Head_and_Esophagus / Sample_Type by Project: Shred V9 | 2.08e-03 | 180 | 17 | 2 | 886ebaf9cf8992e8dd13fca799a1d1a2a9ce73d8 | |
| ToppCell | 10x5'-GI_small-bowel-Lymphocytic_B_plasma-Plasma_cells|GI_small-bowel / Manually curated celltypes from each tissue | 2.10e-03 | 181 | 17 | 2 | a0549a8c2b5b30e91fae3052f398e48baa45d7ff | |
| ToppCell | 10x5'-GI_small-bowel-Lymphocytic_B_plasma|GI_small-bowel / Manually curated celltypes from each tissue | 2.10e-03 | 181 | 17 | 2 | 9b33f531c8ac776706ec7e2d47e95ba30b6ce13c | |
| ToppCell | droplet-Heart-nan-24m-Endothelial|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.10e-03 | 181 | 17 | 2 | 859c40889ede2cbf374c4d2efbb72dc3bc6441f5 | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Epithelial-Renal_corpuscle_epithelial_cell-parietal_epithelial_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.10e-03 | 181 | 17 | 2 | 5f2d3a08577c440c944778d07aa993c6e7873f3d | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Epithelial-Renal_corpuscle_epithelial_cell-parietal_epithelial_cell-Parietal_Epithelial_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.10e-03 | 181 | 17 | 2 | c7c5f7d4c397b4613c772413a0a679377efffff3 | |
| ToppCell | Fetal_29-31_weeks-Endothelial-endothelial_cell_of_vein-D150|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 2.15e-03 | 183 | 17 | 2 | c1297d8eddfc7132e84ceef14f01b6281f9d0f6a | |
| ToppCell | facs-Pancreas-Exocrine-18m-Endothelial|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.15e-03 | 183 | 17 | 2 | c7ef8ee2b3fcfa69cea0fdcb2041674b832933db | |
| ToppCell | facs-Pancreas-Exocrine-18m-Endothelial-nan|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.15e-03 | 183 | 17 | 2 | 92eee4bdd84965ae0bd1ed1c7f26a3b83ad0cdac | |
| ToppCell | facs-Pancreas-Exocrine-18m-Endothelial-endothelial_cell|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.15e-03 | 183 | 17 | 2 | c9d9d7dd629ce6787502103b158a07e8684a66f8 | |
| ToppCell | PND14-Endothelial-Endothelial_blood-vessel-Microvascular_EC-CAP2-CAP2_prolif|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.15e-03 | 183 | 17 | 2 | 3ef9ac1ae13b6172f9121ab1c129ecaa0fef460f | |
| ToppCell | tumor_Lung-Myeloid_cells-Undetermined|tumor_Lung / Location, Cell class and cell subclass | 2.15e-03 | 183 | 17 | 2 | 7ef79365514e62dfc2e182e873e2b413d4f46b46 | |
| ToppCell | PCW_10-12-Endothelial-Endothelial_mature-endo_arterial_(9)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 2.17e-03 | 184 | 17 | 2 | a809b0fa52df8a159f60f87eefcef61220af5e34 | |
| ToppCell | droplet-Heart-4Chambers-21m-Endothelial|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.17e-03 | 184 | 17 | 2 | f17d713af4a97dff4eeeab24c405677ef2ffcf84 | |
| ToppCell | 3'-GW_trimst-1.5-SmallIntestine-Epithelial-neuro-epithelial-EECs|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.20e-03 | 185 | 17 | 2 | d42f6722a6771752cd744146a09e2ead9b7252bc | |
| ToppCell | systemic_lupus_erythematosus-managed-Myeloid-plasmacytoid_dendritic_cell-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 2.20e-03 | 185 | 17 | 2 | cc5152d3055375172bdf84f442b233c8fbd422b3 | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Renal_corpuscle_epithelial_cell-parietal_epithelial_cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 2.20e-03 | 185 | 17 | 2 | 34fcfd635c828dad9643bbf1c908d79282d6f5d9 | |
| ToppCell | normal-na-Myeloid-plasmacytoid_dendritic_cell-male|normal / PBMC cell types (v2) per disease, treatment status, and sex | 2.20e-03 | 185 | 17 | 2 | 3091870a5bf8ecb963e560b47c8502bae367416c | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Renal_corpuscle_epithelial_cell-parietal_epithelial_cell-Parietal_Epithelial_Cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 2.20e-03 | 185 | 17 | 2 | 8816f2909ed11833ff3d0ed96b9cb6d6fe9e1578 | |
| ToppCell | Multiple_Sclerosis-Myeloid-pDC|Multiple_Sclerosis / Disease, Lineage and Cell Type | 2.22e-03 | 186 | 17 | 2 | 330a4f669adea91ff9f2dff2de2210f5e3401e19 | |
| ToppCell | healthy_donor-Lymphocytic-Dendritic|healthy_donor / Disease condition, Lineage, Cell class and subclass | 2.22e-03 | 186 | 17 | 2 | 916f2aeea4989ba7a29e071e348a51010f010223 | |
| ToppCell | control-Myeloid-pDC|control / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 2.22e-03 | 186 | 17 | 2 | fe31e9cf4575ee40b50489593c51d8c36c3cc532 | |
| ToppCell | healthy_donor-Lymphocytic-Dendritic-pDC|healthy_donor / Disease condition, Lineage, Cell class and subclass | 2.22e-03 | 186 | 17 | 2 | 45f66619e45d590c7365a51782d4ac46b7d31fde | |
| ToppCell | control-Myeloid-pDC|Myeloid / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 2.22e-03 | 186 | 17 | 2 | fccee4cfcc887358cf916d974f29627095b5ad9c | |
| ToppCell | (2)_5-FU-(2)_LEPR+_perivascular_cells_and_VE-Cad+_vascular_cells_(mixed)|(2)_5-FU / Stress and Cell class | 2.24e-03 | 187 | 17 | 2 | 6bbf0f7fe203274dae8d582652f35cd3187c0065 | |
| ToppCell | IIH-pDC-|IIH / Condition, Cell_class and T cell subcluster | 2.24e-03 | 187 | 17 | 2 | ad87b146ea8dd9f695e722f8f0e8e1057c7f3167 | |
| ToppCell | LAM-Lymphoid-pDC|Lymphoid / Condition, Lineage and Cell class | 2.24e-03 | 187 | 17 | 2 | 4d9ffd2bbdf1c9869e28991ce9331e4ccf3c0166 | |
| ToppCell | IIH-pDC|IIH / Condition, Cell_class and T cell subcluster | 2.24e-03 | 187 | 17 | 2 | 5e59e9153a18bcfb5c8dc94599080216661de7ce | |
| ToppCell | Children_(3_yrs)-Endothelial-endothelial_cell_of_vein|Children_(3_yrs) / Lineage, Cell type, age group and donor | 2.24e-03 | 187 | 17 | 2 | e35716f8b482be3bf5ab79f087a9caf67a9d197a | |
| ToppCell | systemic_lupus_erythematosus-flare-Myeloid-plasmacytoid_dendritic_cell-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 2.24e-03 | 187 | 17 | 2 | d3563bb087e476baea5b59389e4d34d0ff98cac5 | |
| ToppCell | control-pDC|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 2.24e-03 | 187 | 17 | 2 | c78aee98b32719aa45811b620fc97be1ecf5fd53 | |
| ToppCell | TCGA-Breast-Primary_Tumor-Breast_Carcinoma-Infiltrating_Lobular_Carcinoma-6|TCGA-Breast / Sample_Type by Project: Shred V9 | 2.27e-03 | 188 | 17 | 2 | c90669b51e1902fe7726555290c91c92a911df83 | |
| ToppCell | droplet-Fat-Scat-21m-Endothelial-Cd36+|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.27e-03 | 188 | 17 | 2 | 8671fdbc4138e6f9559920779c98628ed80f0da3 | |
| ToppCell | COVID-19-lung-Vein_EC|lung / Disease (COVID-19 only), tissue and cell type | 2.27e-03 | 188 | 17 | 2 | d582b76fc2faac526c9bf97503041129e1a6a211 | |
| ToppCell | renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 2.29e-03 | 189 | 17 | 2 | 28b502611829e4a24caff2562545c7db97686099 | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.29e-03 | 189 | 17 | 2 | 3b48b0d220cc24d5170713d61fa91f5bb6c21841 | |
| ToppCell | control-immature_Neutrophil|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 2.29e-03 | 189 | 17 | 2 | bdfd120900ba58d5e54765f7b576e1f8cc2401bf | |
| ToppCell | 3'_v3-lymph-node_spleen-Myeloid_Dendritic-pDC|lymph-node_spleen / Manually curated celltypes from each tissue | 2.29e-03 | 189 | 17 | 2 | 6c2ace61a7d62bcf7e76b73e2da8b722d03e713b | |
| ToppCell | droplet-Fat-Scat-21m-Endothelial|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.31e-03 | 190 | 17 | 2 | dd89ef1ecea20b2f6fbdc6cea4ca41b28b3ed822 | |
| ToppCell | ASK454-Epithelial-Ciliated|Epithelial / Donor, Lineage and Cell class of Lung cells from Dropseq | 2.31e-03 | 190 | 17 | 2 | 5cea6480f08253d7adf484e511d3fdfa96641268 | |
| ToppCell | droplet-Pancreas-PANCREAS-30m-Endothelial-endothelial_cell|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.31e-03 | 190 | 17 | 2 | 9d5242759546be0089981ef1877e4ed5f81face5 | |
| ToppCell | 3'_v3-bone_marrow-Myeloid_Dendritic-pDC|bone_marrow / Manually curated celltypes from each tissue | 2.31e-03 | 190 | 17 | 2 | dde0e34f6a06cdbbb65c86472360c09f0279a572 | |
| ToppCell | droplet-Fat-Scat-21m-Endothelial-endothelial_cell|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.31e-03 | 190 | 17 | 2 | d3e46cf800a07ca9b01c78192962d223b9785d05 | |
| ToppCell | Endothelial-A-Donor_06|World / lung cells shred on cell class, cell subclass, sample id | 2.31e-03 | 190 | 17 | 2 | 6e83fa0eb8cabe0ffb35375f16e6bf3755ec4977 | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_adventitial_fibro_(10)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 2.31e-03 | 190 | 17 | 2 | 4f775ee24b14733f06ae40b45f2dc1a0f0df0705 | |
| ToppCell | Adult-Mesenchymal-matrix_fibroblast_2_cell-D175|Adult / Lineage, Cell type, age group and donor | 2.31e-03 | 190 | 17 | 2 | 7dcca3469f3a3b70db0420cb94f7765f39492f06 | |
| ToppCell | MS-pDC-|MS / Condition, Cell_class and T cell subcluster | 2.31e-03 | 190 | 17 | 2 | f56ec302d556ace4f7609017a35c311cf43aa8a5 | |
| ToppCell | MS-pDC|MS / Condition, Cell_class and T cell subcluster | 2.31e-03 | 190 | 17 | 2 | f41d7ab7d7fbcd73fddb6c3533c6a3e642e3d07f | |
| ToppCell | droplet-Heart-HEART-1m-Endothelial-endocardial_endothelial_cells|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.34e-03 | 191 | 17 | 2 | 4bfdf44d4402a42530d30c89d94946acdda4321b | |
| Drug | acetyl tert-butyl dimethylindan | 4.63e-07 | 2 | 16 | 2 | ctd:C033118 | |
| Drug | 2-Chloroestradiol | 4.63e-07 | 2 | 16 | 2 | CID000067343 | |
| Drug | 4-chloroestradiol | 4.63e-07 | 2 | 16 | 2 | CID000067365 | |
| Drug | I 357 | 4.63e-07 | 2 | 16 | 2 | CID000007442 | |
| Drug | pyridate | 4.63e-07 | 2 | 16 | 2 | ctd:C043100 | |
| Drug | ryodipine | 4.63e-07 | 2 | 16 | 2 | ctd:C045912 | |
| Drug | Chlorobenzenes | 4.63e-07 | 2 | 16 | 2 | ctd:D002722 | |
| Drug | 5-acetyl-1,1,2,6-tetramethyl-3-isopropylindane | 4.63e-07 | 2 | 16 | 2 | ctd:C110695 | |
| Drug | Melengestrol Acetate | 4.63e-07 | 2 | 16 | 2 | ctd:D008552 | |
| Drug | butyl-methoxydibenzoylmethane | 4.63e-07 | 2 | 16 | 2 | ctd:C474135 | |
| Drug | cyoctol | 4.63e-07 | 2 | 16 | 2 | CID000055994 | |
| Drug | temsirolimus | 5.71e-07 | 24 | 16 | 3 | ctd:C401859 | |
| Drug | 2-(((3,5-dichlorophenyl)carbamoyl)oxy)-2-methyl-3-butenoic acid | 1.39e-06 | 3 | 16 | 2 | ctd:C101851 | |
| Drug | Nafoxidine | 1.39e-06 | 3 | 16 | 2 | ctd:D009256 | |
| Drug | DHTH | 1.39e-06 | 3 | 16 | 2 | CID000160230 | |
| Drug | p-tert-amylphenol | 1.39e-06 | 3 | 16 | 2 | ctd:C019566 | |
| Drug | Benzophenones | 1.39e-06 | 3 | 16 | 2 | ctd:D001577 | |
| Drug | Chromans | 1.39e-06 | 3 | 16 | 2 | ctd:D002839 | |
| Drug | 2,4,6-trichlorophenyl-4'-aminophenyl ether | 1.39e-06 | 3 | 16 | 2 | ctd:C067259 | |
| Drug | 4-hydroxybenzophenone | 1.39e-06 | 3 | 16 | 2 | ctd:C024292 | |
| Drug | N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide | 1.39e-06 | 32 | 16 | 3 | ctd:C451426 | |
| Drug | lycopene | 2.56e-06 | 143 | 16 | 4 | ctd:C015329 | |
| Drug | resibufogenin | 2.56e-06 | 39 | 16 | 3 | CID000010063 | |
| Drug | 9,10-dihydrophenanthrene | 2.78e-06 | 4 | 16 | 2 | CID000013058 | |
| Drug | laurolactam | 2.78e-06 | 4 | 16 | 2 | ctd:C474694 | |
| Drug | chloropropylate | 2.78e-06 | 4 | 16 | 2 | ctd:C004663 | |
| Drug | phantolid | 2.78e-06 | 4 | 16 | 2 | ctd:C033117 | |
| Drug | 4,4'-dihydroxybiphenyl | 2.78e-06 | 4 | 16 | 2 | ctd:C027439 | |
| Drug | Levonorgestrel | 2.78e-06 | 4 | 16 | 2 | DB00367 | |
| Drug | 11-ketotestosterone | 2.78e-06 | 4 | 16 | 2 | ctd:C003600 | |
| Drug | Fluoxymesterone | 2.78e-06 | 4 | 16 | 2 | DB01185 | |
| Drug | 2-sec-butylphenol | 2.78e-06 | 4 | 16 | 2 | ctd:C033932 | |
| Drug | testosterone decanoate | 2.78e-06 | 4 | 16 | 2 | CID000155143 | |
| Drug | isobutyl-4-hydroxybenzoate | 2.78e-06 | 4 | 16 | 2 | ctd:C045922 | |
| Drug | isofenphos | 2.78e-06 | 4 | 16 | 2 | ctd:C035019 | |
| Drug | AC1L1VK9 | 2.78e-06 | 4 | 16 | 2 | CID000036323 | |
| Drug | ethyl bromophos | 2.78e-06 | 4 | 16 | 2 | ctd:C041062 | |
| Drug | taleranol | 2.78e-06 | 4 | 16 | 2 | ctd:C028226 | |
| Drug | Phenylphosphonothioic Acid, 2-Ethyl 2-(4-Nitrophenyl) Ester | 2.78e-06 | 4 | 16 | 2 | ctd:D004849 | |
| Drug | ciclesonide | 2.78e-06 | 4 | 16 | 2 | ctd:C120481 | |
| Drug | 2-(4-hydroxyphenyl)-3-methyl-1-(4-(2-piperidin-1-yl-ethoxy)-benzyl)-1H-indol-5-ol | 2.78e-06 | 4 | 16 | 2 | ctd:C439584 | |
| Drug | dichlofenthion | 2.78e-06 | 4 | 16 | 2 | ctd:C011445 | |
| Drug | AC1L1FBN | 2.78e-06 | 4 | 16 | 2 | CID000003167 | |
| Drug | chlorobenzilate | 4.62e-06 | 5 | 16 | 2 | ctd:C004659 | |
| Drug | AC1O5TI3 | 4.62e-06 | 5 | 16 | 2 | CID006440391 | |
| Drug | tolclofos-methyl | 4.62e-06 | 5 | 16 | 2 | ctd:C426783 | |
| Drug | 2,4',5-trichlorobiphenyl | 4.62e-06 | 5 | 16 | 2 | ctd:C015550 | |
| Drug | prothiophos | 4.62e-06 | 5 | 16 | 2 | ctd:C032072 | |
| Drug | isobutylparaben | 4.62e-06 | 5 | 16 | 2 | ctd:C471067 | |
| Drug | Hexylresorcinol | 4.62e-06 | 5 | 16 | 2 | ctd:D006604 | |
| Drug | flucythrinate | 4.62e-06 | 5 | 16 | 2 | ctd:C027975 | |
| Drug | 3',5'-dichloro-2-hydroxy-2-methylbut-3-enanilide | 4.62e-06 | 5 | 16 | 2 | CID000115209 | |
| Drug | 3-benzylidene camphor | 4.62e-06 | 5 | 16 | 2 | ctd:C511303 | |
| Drug | zindoxifene | 4.62e-06 | 5 | 16 | 2 | CID000065645 | |
| Drug | Leptophos | 4.62e-06 | 5 | 16 | 2 | ctd:D010773 | |
| Drug | 2,2',4,5'-tetrabromodiphenyl ether | 4.62e-06 | 5 | 16 | 2 | ctd:C572625 | |
| Drug | homosalate | 4.62e-06 | 5 | 16 | 2 | ctd:C060446 | |
| Drug | Norethynodrel | 4.62e-06 | 5 | 16 | 2 | ctd:D009641 | |
| Drug | ethion | 4.62e-06 | 5 | 16 | 2 | ctd:C100038 | |
| Drug | letrozole | 4.83e-06 | 48 | 16 | 3 | ctd:C067431 | |
| Drug | 3',5'-dichloro-2-hydroxy-2-methylbut-3-enanilide | 6.93e-06 | 6 | 16 | 2 | ctd:C101850 | |
| Drug | 2',3',4',5'-tetrachloro-4-biphenylol | 6.93e-06 | 6 | 16 | 2 | ctd:C104006 | |
| Drug | isopropyl 4,4'-dibromobenzilate | 6.93e-06 | 6 | 16 | 2 | ctd:C038267 | |
| Drug | equiguard | 6.93e-06 | 6 | 16 | 2 | ctd:C498475 | |
| Drug | Danazol | 6.93e-06 | 6 | 16 | 2 | DB01406 | |
| Drug | alpha-terthienyl | 6.93e-06 | 6 | 16 | 2 | ctd:C019101 | |
| Drug | 2,6-di-tert-butyl-4-hydroxy-4-methyl-2,5-cyclohexadien-1-one | 6.93e-06 | 6 | 16 | 2 | ctd:C038639 | |
| Drug | 3,5-di-tert-butyl-4-hydroxybenzaldehyde | 6.93e-06 | 6 | 16 | 2 | ctd:C513957 | |
| Drug | CB 1093 | 6.93e-06 | 6 | 16 | 2 | ctd:C103436 | |
| Drug | Equilin | 6.93e-06 | 6 | 16 | 2 | ctd:D004857 | |
| Drug | tetralin | 6.93e-06 | 6 | 16 | 2 | ctd:C095210 | |
| Drug | di-n-butyl phthalate | 8.14e-06 | 57 | 16 | 3 | CID000003026 | |
| Drug | Nadolol [42200-33-9]; Up 200; 13uM; PC3; HT_HG-U133A | 8.58e-06 | 194 | 16 | 4 | 4021_UP | |
| Drug | Doxycycline hydrochloride [10592-13-9]; Up 200; 8.4uM; MCF7; HT_HG-U133A | 9.30e-06 | 198 | 16 | 4 | 3479_UP | |
| Drug | pendimethalin | 9.70e-06 | 7 | 16 | 2 | ctd:C030856 | |
| Drug | 2,4,6-trichlorophenyl 4-nitrophenyl ether | 9.70e-06 | 7 | 16 | 2 | ctd:C010422 | |
| Drug | 2,2-di(4-methacryloxyphenyl)propane | 9.70e-06 | 7 | 16 | 2 | ctd:C002462 | |
| Drug | DIBA-1 | 9.70e-06 | 7 | 16 | 2 | ctd:C100805 | |
| Drug | ethyl myristate | 9.70e-06 | 7 | 16 | 2 | ctd:C032396 | |
| Drug | boldenone undecylenate | 9.70e-06 | 7 | 16 | 2 | ctd:C001371 | |
| Drug | lacidipine | 9.70e-06 | 7 | 16 | 2 | ctd:C060285 | |
| Drug | octyldimethyl-p-aminobenzoic acid | 9.70e-06 | 7 | 16 | 2 | CID000042851 | |
| Drug | atamestane | 9.70e-06 | 7 | 16 | 2 | CID000057050 | |
| Drug | lercanidipine | 9.70e-06 | 7 | 16 | 2 | ctd:C060343 | |
| Drug | 3-phenoxybenzoic acid | 9.70e-06 | 7 | 16 | 2 | ctd:C017618 | |
| Drug | lead thiocyanate | 9.70e-06 | 7 | 16 | 2 | CID000011616 | |
| Drug | di-n-octyl phthalate | 1.29e-05 | 8 | 16 | 2 | ctd:C010715 | |
| Drug | aroclor 1221 | 1.29e-05 | 8 | 16 | 2 | ctd:C032739 | |
| Drug | Nisoldipine | 1.29e-05 | 8 | 16 | 2 | ctd:D015737 | |
| Drug | 4-cumylphenol | 1.29e-05 | 8 | 16 | 2 | ctd:C516284 | |
| Drug | tolclofos-methyl | 1.29e-05 | 8 | 16 | 2 | CID000091664 | |
| Drug | Colchicine | 1.46e-05 | 222 | 16 | 4 | ctd:D003078 | |
| Drug | methoxychlor | 1.65e-05 | 72 | 16 | 3 | CID000004115 | |
| Drug | pirarubicin | 1.66e-05 | 9 | 16 | 2 | ctd:C027260 | |
| Drug | Androstenediol | 1.66e-05 | 9 | 16 | 2 | ctd:D015114 | |
| Drug | galaxolide | 1.66e-05 | 9 | 16 | 2 | ctd:C033119 | |
| Drug | Oxymetholone | 1.66e-05 | 9 | 16 | 2 | ctd:D010110 | |
| Drug | 4-phenylphenol | 1.66e-05 | 9 | 16 | 2 | ctd:C019046 | |
| Drug | Goserelin | 1.66e-05 | 9 | 16 | 2 | ctd:D017273 | |
| Drug | propamocarb | 1.66e-05 | 9 | 16 | 2 | CID000032490 | |
| Disease | leukemia | 3.37e-06 | 55 | 16 | 3 | C0023418 | |
| Disease | prostatic hypertrophy (implicated_via_orthology) | 4.13e-06 | 6 | 16 | 2 | DOID:11132 (implicated_via_orthology) | |
| Disease | Prostatic Intraepithelial Neoplasias | 1.51e-05 | 11 | 16 | 2 | C0282612 | |
| Disease | prostate cancer (is_implicated_in) | 3.28e-05 | 117 | 16 | 3 | DOID:10283 (is_implicated_in) | |
| Disease | in situ carcinoma (is_marker_for) | 5.75e-05 | 21 | 16 | 2 | DOID:8719 (is_marker_for) | |
| Disease | Neoplasm of the genitourinary tract | 7.56e-05 | 24 | 16 | 2 | cv:C0042065 | |
| Disease | Pilocytic Astrocytoma | 8.21e-05 | 25 | 16 | 2 | C0334583 | |
| Disease | Cerebral Astrocytoma | 8.21e-05 | 25 | 16 | 2 | C0750935 | |
| Disease | Intracranial Astrocytoma | 8.21e-05 | 25 | 16 | 2 | C0750936 | |
| Disease | Astrocytoma | 8.21e-05 | 25 | 16 | 2 | C0004114 | |
| Disease | Juvenile Pilocytic Astrocytoma | 8.21e-05 | 25 | 16 | 2 | C0280783 | |
| Disease | Diffuse Astrocytoma | 8.21e-05 | 25 | 16 | 2 | C0280785 | |
| Disease | Grade I Astrocytoma | 8.21e-05 | 25 | 16 | 2 | C1704230 | |
| Disease | Subependymal Giant Cell Astrocytoma | 8.21e-05 | 25 | 16 | 2 | C0205768 | |
| Disease | Mixed oligoastrocytoma | 8.21e-05 | 25 | 16 | 2 | C0547065 | |
| Disease | Childhood Cerebral Astrocytoma | 8.21e-05 | 25 | 16 | 2 | C0338070 | |
| Disease | Gemistocytic astrocytoma | 8.89e-05 | 26 | 16 | 2 | C0334581 | |
| Disease | Protoplasmic astrocytoma | 8.89e-05 | 26 | 16 | 2 | C0334580 | |
| Disease | Fibrillary Astrocytoma | 8.89e-05 | 26 | 16 | 2 | C0334582 | |
| Disease | Anaplastic astrocytoma | 9.60e-05 | 27 | 16 | 2 | C0334579 | |
| Disease | Subfertility, Female | 1.03e-04 | 28 | 16 | 2 | C0341869 | |
| Disease | Sterility, Postpartum | 1.03e-04 | 28 | 16 | 2 | C0038279 | |
| Disease | Female sterility | 1.03e-04 | 28 | 16 | 2 | C0917730 | |
| Disease | Female infertility | 1.03e-04 | 28 | 16 | 2 | C0021361 | |
| Disease | Neoplasm of uncertain or unknown behavior of ovary | 1.11e-04 | 29 | 16 | 2 | C0496920 | |
| Disease | Ovarian Carcinoma | 1.19e-04 | 30 | 16 | 2 | C0029925 | |
| Disease | endometrial cancer (is_implicated_in) | 1.72e-04 | 36 | 16 | 2 | DOID:1380 (is_implicated_in) | |
| Disease | ductal carcinoma in situ (is_marker_for) | 2.02e-04 | 39 | 16 | 2 | DOID:0060074 (is_marker_for) | |
| Disease | Neoplasm Recurrence, Local | 2.02e-04 | 39 | 16 | 2 | C0027643 | |
| Disease | Breast adenocarcinoma | 2.23e-04 | 41 | 16 | 2 | C0858252 | |
| Disease | Neoplasm of uncertain or unknown behavior of breast | 2.23e-04 | 41 | 16 | 2 | C0496956 | |
| Disease | Prostatic Neoplasms | 2.80e-04 | 616 | 16 | 4 | C0033578 | |
| Disease | Malignant neoplasm of prostate | 2.80e-04 | 616 | 16 | 4 | C0376358 | |
| Disease | Male sterility | 3.06e-04 | 48 | 16 | 2 | C0917731 | |
| Disease | Male infertility | 3.06e-04 | 48 | 16 | 2 | C0021364 | |
| Disease | Subfertility, Male | 3.06e-04 | 48 | 16 | 2 | C0848676 | |
| Disease | aortic measurement | 3.14e-04 | 251 | 16 | 3 | EFO_0020865 | |
| Disease | Endometrial Neoplasms | 4.48e-04 | 58 | 16 | 2 | C0014170 | |
| Disease | acute kidney failure (biomarker_via_orthology) | 4.95e-04 | 61 | 16 | 2 | DOID:3021 (biomarker_via_orthology) | |
| Disease | breast carcinoma (is_marker_for) | 5.79e-04 | 66 | 16 | 2 | DOID:3459 (is_marker_for) |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| MYCFEMHCKHVRFLM | 336 | Q6NVV9 | |
| YAKMGEMMLALFRHH | 181 | P17342 | |
| RDRHLDQIMMCSMYG | 696 | P06400 | |
| HMSNKGMEHLYSMKC | 516 | P03372 | |
| EKVMHMFKGCRREDM | 456 | Q92614 | |
| MHKSRMYSQCVRMRH | 776 | P10275 | |
| MMEARCRKMAHISKY | 491 | P52701 | |
| MNRHLHEYMEMCSMK | 491 | Q0D2I5 | |
| HEYMEMCSMKRGLDV | 496 | Q0D2I5 | |
| RHLHEYMEMCSMKRG | 451 | Q5TF58 | |
| CHLLHYMMIMSLHRC | 141 | Q8NH06 | |
| LMIHMFHCRMVLTYH | 196 | Q9UBY8 | |
| KMRMMARAARMLHHC | 841 | O95398 | |
| MYKMHRGHDSMHVEM | 41 | Q8N4F7 | |
| MKRHEMVAKHLVMFY | 1 | Q03924 | |
| QHMSMYDGRKMHECH | 211 | Q96PQ6 | |
| YGGHKDMIMCMTIHK | 1776 | Q9H2Y7 | |
| DMKDRRMHHGATVMG | 506 | Q2WGJ6 |